Exelixis (EXEL) Stock Forecast & Price Target

$34.04 +0.23 (+0.68%)

(As of 11:10 AM ET)

Exelixis - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 19 Analyst Ratings

Sell
1

Hold
7

Buy
11

Based on 19 Wall Street analysts who have issued ratings for Exelixis in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 1 has given a sell rating, 7 have given a hold rating, and 11 have given a buy rating for EXEL.

Consensus Price Target

$32.44
-4.71% Downside

According to the 19 analysts' twelve-month price targets for Exelixis, the average price target is $32.44. The highest price target for EXEL is $40.00, while the lowest price target for EXEL is $25.00. The average price target represents a forecasted downside of -4.71% from the current price of $34.04.

Get the Latest News and Ratings for EXEL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Exelixis and its competitors.

EXEL Analyst Ratings Over Time

Type	Current Forecast 12/31/23 to 12/30/24	1 Month Ago 12/1/23 to 11/30/24	3 Months Ago 10/2/23 to 10/1/24	1 Year Ago 12/31/22 to 12/31/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	14 Buy rating(s)	10 Buy rating(s)	14 Buy rating(s)
Hold	7 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$32.44	$31.44	$27.67	$25.84
Forecasted Upside	-4.71% Downside	-13.76% Downside	5.20% Upside	7.72% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Kamala’s final humiliation (Ad)

The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware of… yet have the potential to deliver colossal returns over the next four years. I’m not talking about Tesla, Palantir, or anything else you’ve heard parroted by the mainstream financial press. No. These are Trump’s Secret Stocks.

It’s all waiting for you here.

EXEL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EXEL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Exelixis Stock vs. The Competition

Type	Exelixis	Medical Companies	S&P 500
Consensus Rating Score	2.53	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	-4.06% Downside	24,180.63% Upside	14.07% Upside
News Sentiment Rating	Neutral News See Recent EXEL News	Positive News	Neutral News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/23/2024	Brookline Capital Management 2 of 5 stars	L. Cann Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
12/20/2024	BMO Capital Markets 4 of 5 stars	E. Darout Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$36.00 ➝ $40.00	+18.76%
12/17/2024	Bank of America 3 of 5 stars		Downgrade	Buy ➝ Neutral	$35.00 ➝ $39.00	+8.12%
10/30/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Loganathan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$23.00 ➝ $29.00	-11.69%
10/30/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$32.00 ➝ $33.00	+0.49%
10/30/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$33.00 ➝ $36.00	+10.67%
Get the Latest News and Ratings for EXEL and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.
10/30/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$34.00 ➝ $34.00	+4.20%
10/30/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$32.00 ➝ $36.00	+8.47%
10/30/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$33.00 ➝ $38.00	+14.49%
10/21/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$27.00 ➝ $34.00	+18.55%
10/16/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$26.00 ➝ $30.00	+5.26%
10/15/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Shibutani Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
10/11/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Outperform ➝ Market Outperform	$29.00 ➝ $29.00	+10.35%
10/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$26.00 ➝ $28.00	+6.63%
9/19/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Verma Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$30.00	+11.86%
9/18/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$29.00 ➝ $29.00	+5.07%
7/30/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$29.00 ➝ $29.00	+25.22%
5/1/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
4/11/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight	$25.00	+5.57%
12/19/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$27.00	+15.68%
12/15/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$31.00	+32.99%
8/8/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Liu Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
8/8/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$18.00	-11.11%
8/8/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$18.00	-11.11%
3/3/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$24.00	+43.97%
1/26/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$29.00	+67.34%
1/9/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$21.00 ➝ $20.00	+15.81%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 11:32 AM ET.

EXEL Forecast - Frequently Asked Questions

: According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Exelixis is $32.44, with a high forecast of $40.00 and a low forecast of $25.00.
: 19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There is currently 1 sell rating, 7 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EXEL shares.
: According to analysts, Exelixis's stock has a predicted downside of -4.71% based on their 12-month stock forecasts.
: Over the previous 90 days, Exelixis's stock had 2 downgrades and 1 upgrade by analysts.
: Exelixis has been rated by research analysts at Bank of America, BMO Capital Markets, Brookline Capital Management, Guggenheim, JMP Securities, Morgan Stanley, Piper Sandler, Royal Bank of Canada, Stephens, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Truist Financial, and Wells Fargo & Company in the past 90 days.
: Analysts like Exelixis less than other "medical" companies. The consensus rating score for Exelixis is 2.53 while the average consensus rating score for "medical" companies is 2.81. Learn more on how EXEL compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

No one’s talking about these Trump trades (Ad)

As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”

Go here to see how you can start accessing these opportunities today

This page (NASDAQ:EXEL) was last updated on 12/30/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exelixis (EXEL) Stock Forecast & Price Target